ClinicalTrials.gg
CompletedNCT00423319Updated May 14, 2014Results posted

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

A Phase 3 interventional study of Enoxaparin and Apixaban in Deep Vein Thrombosis and Pulmonary Embolism, sponsored by Bristol-Myers Squibb. Completed at 143 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-14.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,407
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing enoxaparin in Venous Thrombosis — 3 open to participants now, 3 under way, 1 of them phase 3. Enoxaparin · Venous Thrombosis.

Enrollment
3rd of 42
5,407 · median 114
Started
2007
with 3 others
Phase 3
5 of 42
none open now
Registered
6th of 42
by date
Lead sponsor
1 of 42
Bristol-Myers Squibb

Among the 42 studies testing enoxaparin in Venous Thrombosis, this one is the 3rd largest by enrollment, is one of 4 that started in 2007, is one of 5 in phase 3, and was the 6th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

3 of the 42 studies testing enoxaparin in Venous Thrombosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About enoxaparin

Enoxaparin: first FDA approval 1993 (LOVENOX (PRESERVATIVE FREE)), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing enoxaparin in Venous Thrombosis, or all of them as a file.
02

Study summary

The purpose of this study is to learn whether apixaban can prevent the blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism) that sometimes occur after hip replacement surgery and to learn how apixaban compares with enoxaparin in preventing these clots. The safety of apixaban will also be studied

03

Conditions studied

  • Deep Vein Thrombosis
  • Pulmonary Embolism

Keywords

  • Prevention of deep vein thrombosis and
  • pulmonary embolism after total hip replacement surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • Patients undergoing elective unilateral total hip replacement or a revision of at least 1 component of a total hip replacement.
  • Patients who were willing and able to undergo bilateral ascending contrast venography
  • Either sex, any race, 18 years and older

Key Exclusion Criteria

  • Known or suspected bleeding or coagulation disorder in the patient or his or her first-degree relative
  • Known or suspected history of heparin-induced thrombocytopenia
  • Known coagulopathy
  • Active bleeding or at high risk for bleeding
  • Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days
  • Active hepatobiliary disease
  • Alcohol and/or substance abuse within the past year
  • Any condition for which surgery or administration of an anticoagulant is
  • Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic blood pressure >180 mm Hg or supine diastolic blood pressure >105 mm Hg
  • laboratory abnormalities at the enrollment visit:
  • \<10 g/dL
  • count \<100,000/mm\^3
  • \<30 mL/min, as estimated by the method of Cockcroft and Gault
  • or aspartate aminotransferase >2* or a total ≥ 1.5*1 (unless an alternative causative factor such as Gilbert's syndrome was identified)
  • Need for ongoing treatment with a parenteral or oral anticoagulant (eg, subjects with mechanical valves, warfarin eligible atrial fibrillation)
  • Current use of dextrans or fibrinolytics
  • Treatment with medications affecting coagulation or platelet function
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
5,407 participants (actual)

Study arms

  • Active comparator
    Apixaban, 2.5 mg BID plus placebo

    Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)

    Drug: Apixaban · Drug: Enoxaparin-matching placebo

  • Experimental
    Enoxaparin, 40 mg QD plus placebo

    Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID

    Drug: Enoxaparin · Drug: Apixaban-matching placebo

Interventions

  • Subcutaneous, 40 mg, once daily, 5 weeks

    Also known as: Lovenox®

  • Oral tablets, 2.5 mg, twice daily, 5weeks

    Also known as: BMS-562247, Eliquis®

  • DrugEnoxaparin-matching placebo

    Administered as injection

  • DrugApixaban-matching placebo

    Administered as oral tablets

06

What researchers measure

Primary outcomes

  1. Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period

    Event rate=Number of events divided by the number of patients evaluated. A mandatory bilateral ascending contrast venogram was to be obtained on Day 35 (± 3). Patients with confirmed symptomatic DVT at any time, or asymptomatic DVT upon venography, were to receive treatment for DVT according to the investigator's standard of care. Signs and symptoms suggestive of VTE included, but were not limited to: 1) lower extremity DVT: erythema, warmth, pain, swelling, tenderness; and 2) PE: pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia. Intended Treatment Period started on day of randomization and, for patients who received treatment, ended at the later of 2 days after last dose of study drug or 38 days after the first dose (presurgery) of study drug. For randomized patients who did not receive study drug, the period ended 38 days after randomization.

    Time frame: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose

Secondary outcomes

  1. Rate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period

    Event rate=Number of events divided by the number of patients evaluated. Each patient was categorized as having no proximal DVT, having proximal DVT, being nonevaluable for proximal DVT, having no distal DVT, having distal DVT, or being nonevaluable for distal DVT. Adjudication criteria were: Normal=All deep veins were visualized, and there was no intraluminal filling defect (ILFD). ILFD=An area of reduced, or absent filling, at least partially surrounded with contrast medium in ≥ 2 projections or a lack of filling in a vessel in which there was a cut-off that had the configuration of a thrombus. Indeterminate=A lack of filling of a region of the deep vein system, proximal or distal, without the presence of an ILFD elsewhere in the same region. Not Done=A venography was not performed. Proximal DVT was found if any of the proximal veins had an ILFD. Pulmonary embolism was radiographically (angiography, V/Q scan, computed tomography) determined.

    Time frame: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose

  2. Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period

    VTE=venous thromboembolic event; VTE-related death=combination of fatal or nonfatal PE and symptomatic or asymptomatic DVT. Event rate=Number of events divided by the number of patients evaluated.

    Time frame: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose

  3. Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), Major or CRNM, and Any Bleeding During the Treatment Period

    Event rate=Number of events divided by the number of patients evaluated. Major bleeding event defined as a bleeding event that was 1) Acute clinically overt bleeding accompanied by at least 1 of the following: decrease in hemoglobin of ≥ 2 g/dL over a 24-hour period, transfusion of ≥2 units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intra-spinal, intraocular, pericardial, an operated joint and requires reoperation or intervention, intramuscular with compartment syndrome, or retroperitoneal; 2) Fatal. CRNM was defined as acute clinically overt bleeding that did not satisfy the criteria for a major bleeding event and met at least 1 of the following: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, or hemoptysis. Minor bleeding was defined as an acute clinically overt bleeding event that did not meet the criteria for major bleeding or a CRNM. Fatal bleeding event was defined as bleeding that was the primary

    Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug

  4. Number of Participants With Serious Adverse Events (SAEs), Bleeding Adverse Events (AEs), and Death as Outcome

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. All suspected bleeding events were to be reported by the investigator as either an AE or SAE and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood.

    Time frame: First dose of study drug (presurgery) through 30 days after the last dose of study drug

  5. Number of Participants With a Bleeding-related Adverse Event During the Treatment Period

    All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.

    Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug

  6. Number of Participants With a Bleeding-related Adverse Events During the Treatment Period (Continued)

    All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.

    Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug

  7. Number of Participants With a Bleeding-related Adverse Event During the Treatment Period (Continued)

    All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.

    Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug

  8. Number of Participants With Neurologic Adverse Events With Onset During the Treatment Period

    Neurologic events were based on Medical Dictionary for Regulatory Activities search categories.For new or worsening events that were not related to the site of surgery, additional information was collected on a specific form. In addition, neurology consultation was to be obtained for these patients.

    Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug

  9. Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period

    preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. MA criteria: Hemoglobin: \>2 g/dL decrease from preRx or value ≤ 8 g/dL; hematocrit (%): \<0.75\*preRx; platelet count (\*10\^9 cells/L): \<100,000/mm\^3; erythrocytes (\*10\^6 cells/μL): \<0.75\*preRx level; leukocytes (\*10\^3 cells/μL): \< 0.75\*LLN or \>1.25\*ULN, or if preRx LLN use \< 0.8\*preRx or \>ULN if preRx \>ULN use \>1.2\*preRx or \<LLN; basophils (\*10\^3 cells/μL): \>400/mm\^3; eosinophils (\*10\^3 cells/μL): \> 0.75\*10\^3 cells/μL; lymphocytes (\*10\^3 cells/μL): \>0.75\*10\^3 cells/μL; monocytes (\*10\^3 cells/μL): \>2000/mm\^3; neutrophils (\*10\^3 cells/μL): \<1.0;

    Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug

  10. Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)

    preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Alanine aminotransferase (ALT) (U/L): \>3 \*ULN: alkaline phosphatase (ALP) (U/L): \>2\* ULN; aspartate aminotransferase (ASP) (U/L): \>3 \*ULN; bilirubin, direct (mg/dL): \>2\*ULN; bilirubin, total (mg/dL): \>2\*ULN; BUN (mg/dL): \>2\*ULN; creatinine (mg/dL): \>1.5\*ULN; calcium (mg/dL): \< 0.8\*LLN or \>1.2 \*ULN, or if preRx \<LLN use \<0.75\* preRx or \>ULN if preRx \>ULN use \> 1.25\*preRx or \<LLN; chloride (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use \<0.9\*preRx or \>ULN if preRx \>ULN use \>1.1\* preRx or \<LLN; bicarbonate (mEq/L): \< 0.75\* LLN or \>1.25\*ULN, or if preRx \<LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \<LLN; potassium (mEq/L): \< 0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use \<0.9\*preRx or \>ULN if preRx \>ULN use \>1.1\* preRx or \< LLN; sodium (mEq/L): \<0.95\* LLN or \>1.05×ULN, or if preRx \<LLN use \<0.95\* predose or \>ULN if preRx \>ULN use \>1.05 \*preRx or \< LLN.

    Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug

  11. Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)

    preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Glucose, fasting (mg/dL): \<.8\*LLN or \>1.5\*ULN, or if preRx \<LLN use \<.8\*preRx or \>ULN if preRx \>ULN use \>2\*preRx or \<LLN; protein, total (g/L): If missing preRx use ≥2, or if value ≥4 or preRx =0 or .5 use ≥2, or if preRx=1 use ≥3, or if preRx =2 or 3 use ≥4; creatine kinase (U/L): \>5\*ULN; uric acid (mg/dL): \>.5\* ULN, or if preRx \>ULN use \>2\*preRx; blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx =2 or 3 use ≥4; glucose, urine : If missing preRx use ≥2, or if value ≥4, or if preRx=0 or .5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; RBC, urine (hpf): If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx dose= 1 use ≥3, or if preRx=2 or 3 use ≥4; WBC, urine (h): If missing preRx use ≥2, or if value ≥4, or if preRx =0 or .5 use ≥2, or if preRx =1 use ≥3, or if preRx=2 or 3 use ≥4.

    Time frame: First dose of study drug (presurgery) through 2 days after the last dose of study drug

  12. Number of Participants With Adverse Events Related to Elevations in Liver Function Test Results With Onset During the Treatment Period

    Treatment guidelines were provided for jaundice and elevated results of liver function tests.

    Time frame: First dose of study drug (presurgery) through 30 days after the last dose of study drug

  13. Rates of Adjudicated Myocardial Infarction (MI)/Stroke, MI, Stroke, and Thrombocytopenia During the Intended Treatment Period

    Event rate=Number of events divided by the number of patients evaluated. All suspected events were reported by investigator. Acute MI=the presence of a clinical situation (eg, abnormal history, physical examination, new electrocardiogram changes) suggestive of an MI and at least 1 of the following: elevated creatine kinase (CK)-MB or troponin T or troponin I ≥2\*upper limit of normal (ULN); if CK-MB or troponin values not available, total CK ≥2\*ULN; or new significant (≥0.04 sec) Q waves in ≥2 contiguous leads. Stroke=a new focal neurologic deficit of sudden onset lasting at least 24 hours that was not due to a readily identifiable nonvascular cause. Adjudication classified each reported stroke as primary hemorrhagic, nonhemorrhagic, infarction with hemorrhagic conversion, or unknown type. Thrombocytopenia=after 3 days as drop in platelet count to \<100,000/mm\^3 for patients with a baseline value \>150,000/mm\^3 or a \>50% decline, if the baseline value was ≤150,000/mm\^3.

    Time frame: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose

07

Results

Posted May 14, 2014

Participant flow

Participant flow — Overall Study
MilestoneApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Started27082699
Participants who received treatment26732659
Completed24842447
Not completed224252
Withdrew: Death20
Withdrew: Adverse event93112
Withdrew: Withdrawal by subject8699
Withdrew: Lost to follow-up43
Withdrew: Poor compliance or noncompliance11
Withdrew: No longer meets study criteria1515
Withdrew: Other2322

Outcome measures

PrimaryRate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period

Event rate=Number of events divided by the number of patients evaluated. A mandatory bilateral ascending contrast venogram was to be obtained on Day 35 (± 3). Patients with confirmed symptomatic DVT at any time, or asymptomatic DVT upon venography, were to receive treatment for DVT according to the investigator's standard of care. Signs and symptoms suggestive of VTE included, but were not limited to: 1) lower extremity DVT: erythema, warmth, pain, swelling, tenderness; and 2) PE: pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia. Intended Treatment Period started on day of randomization and, for patients who received treatment, ended at the later of 2 days after last dose of study drug or 38 days after the first dose (presurgery) of study drug. For randomized patients who did not receive study drug, the period ended 38 days after randomization.

Time frame:
Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Reported as:
Number · Percentage of events/patients evaluated
Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period
Percentage of events/patients evaluatedApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period1.39 (0.95 to 2.02)3.86 (3.08 to 4.83)
Statistical analysis
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Farrington-Manning test · p = <0.0001 (Statistically significant at the 1-sided 0.025 level) · Risk ratio (rr): 0.36 · 95% CI 0.22 to 0.54Apixaban-enoxaparin
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Farrington-Manning test · p = <0.0001 (Statistically significant at the 1-sided 0.025 level) · Risk difference: -2.47 · 95% CI -3.54 to 1.50Apixaban-enoxaparin
SecondaryRate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period

Event rate=Number of events divided by the number of patients evaluated. Each patient was categorized as having no proximal DVT, having proximal DVT, being nonevaluable for proximal DVT, having no distal DVT, having distal DVT, or being nonevaluable for distal DVT. Adjudication criteria were: Normal=All deep veins were visualized, and there was no intraluminal filling defect (ILFD). ILFD=An area of reduced, or absent filling, at least partially surrounded with contrast medium in ≥ 2 projections or a lack of filling in a vessel in which there was a cut-off that had the configuration of a thrombus. Indeterminate=A lack of filling of a region of the deep vein system, proximal or distal, without the presence of an ILFD elsewhere in the same region. Not Done=A venography was not performed. Proximal DVT was found if any of the proximal veins had an ILFD. Pulmonary embolism was radiographically (angiography, V/Q scan, computed tomography) determined.

Time frame:
Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Reported as:
Number · Percentage of events/patients evaluated
Rate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period
Percentage of events/patients evaluatedApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Rate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period0.45 (0.24 to 0.85)1.14 (0.77 to 1.69)
Statistical analysis
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Farrington-Manning test · p = <0.0001 (Statistically significant at the 1-sided 0.025 level) · Risk ratio (rr): 0.40 · 95% CI 0.15 to 0.80Apixaban-enoxaparin
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Chi-squared · p = 0.0054 (Statistically significant at the 1-sided 0.025 level) · Risk difference: -0.68 · 95% CI -1.27 to -0.17Apixaban-enoxaparin
SecondaryRates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period

VTE=venous thromboembolic event; VTE-related death=combination of fatal or nonfatal PE and symptomatic or asymptomatic DVT. Event rate=Number of events divided by the number of patients evaluated.

Time frame:
Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Reported as:
Number · Percentage of events/patients evaluated
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period
Percentage of events/patients evaluatedApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
All-cause death0.110.04
VTE-related death0.040.00
PE (fatal or nonfatal)0.110.19
Nonfatal PE0.070.19
All DVT (n=1944, 1911)1.133.56
Symptomatic DVT0.040.19
Asymptomatic DVT (n=1943, 1907)1.083.30
Proximal DVT (n=2196, 2190)0.320.91
Distal DVT (1951, 1908)1.032.99
Symptomatic proximal DVT0.040.15
Asymptomatic proximal DVT (n=2195, 2187)0.270.73
Symptomatic distal DVT0.040.04
Asymptomatic distal DVT (n=1950, 1907)0.972.94
SecondaryRate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), Major or CRNM, and Any Bleeding During the Treatment Period

Event rate=Number of events divided by the number of patients evaluated. Major bleeding event defined as a bleeding event that was 1) Acute clinically overt bleeding accompanied by at least 1 of the following: decrease in hemoglobin of ≥ 2 g/dL over a 24-hour period, transfusion of ≥2 units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intra-spinal, intraocular, pericardial, an operated joint and requires reoperation or intervention, intramuscular with compartment syndrome, or retroperitoneal; 2) Fatal. CRNM was defined as acute clinically overt bleeding that did not satisfy the criteria for a major bleeding event and met at least 1 of the following: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, or hemoptysis. Minor bleeding was defined as an acute clinically overt bleeding event that did not meet the criteria for major bleeding or a CRNM. Fatal bleeding event was defined as bleeding that was the primary

Time frame:
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Reported as:
Number · Percentage of events/patients evaluted
Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), Major or CRNM, and Any Bleeding During the Treatment Period
Percentage of events/patients evalutedApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Major bleeding0.82 (0.54 to 1.25)0.68 (0.42 to 1.08)
CRNM4.08 (3.39 to 4.90)4.51 (3.79 to 5.38)
Major or CRNM4.83 (4.08 to 5.71)5.04 (4.27 to 5.94)
Any bleeding11.71 (10.55 to 12.99)12.56 (11.36 to 13.88)
Statistical analysis
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Chi-squared · p = 0.54 (2-sided P-Value) · Difference in event rates: 0.15 · 95% CI -0.33 to 0.64Major bleeding. Apixaban-enoxaparin
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Chi-squared · p = 0.43 (2-sided P-Value) · Difference in event rates: -0.44 · 95% CI -1.53 to 0.66CRNM. Apixaban-enoxaparin
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Chi-squared · p = 0.72 (2-sided P-Value) · Difference in event rates: -0.21 · 95% CI -1.38 to 0.95Major or CRNM. Apixaban-enoxaparin
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Chi-squared · p = 0.34 (2-sided P-Value) · Difference in event rate: -0.85 · 95% CI -2.61 to 0.90Any bleeding. Apixaban-enoxaparin
SecondaryNumber of Participants With Serious Adverse Events (SAEs), Bleeding Adverse Events (AEs), and Death as Outcome

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. All suspected bleeding events were to be reported by the investigator as either an AE or SAE and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood.

Time frame:
First dose of study drug (presurgery) through 30 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events (SAEs), Bleeding Adverse Events (AEs), and Death as Outcome
ParticipantsApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
SAEs1818
Bleeding AEs1521
Death20
SecondaryNumber of Participants With a Bleeding-related Adverse Event During the Treatment Period

All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.

Time frame:
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With a Bleeding-related Adverse Event During the Treatment Period
ParticipantsApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Postprocedural hematoma2023
Operative hemorrhage1914
Incision site hematoma1410
Incision site hemorrhage1319
Postprocedural hemorrhagic47
Hematuria traumatic11
Periorbital hematoma10
Subcutaneous hematoma10
Traumatic hematoma01
Hematoma3438
Wound hemorrhage1815
Hemorrhage1313
Hematuria4139
Hemorrhage urinary tract11
Urethral hemorrhage02
Epistaxis3325
Hemoptysis31
SecondaryNumber of Participants With a Bleeding-related Adverse Events During the Treatment Period (Continued)

All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.

Time frame:
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With a Bleeding-related Adverse Events During the Treatment Period (Continued)
ParticipantsApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Bloody discharge1613
Catheter site hemorrhage65
Injection site hemorrhage410
Injection site hematoma328
Infusion site hematoma10
Vessel puncture site hematoma10
Hematocrit decreased1821
Red blood cell count decreased1420
Blood urine present86
Blood urine11
Occult blood positive10
Fibrin D dimer increased01
Hematochezia62
Mallory-Weiss Syndrome40
Hematemesis32
Melaena31
Rectal hemorrhage31
Gingival bleeding23
Anal hemorrhage10
Diarrhea hemorrhagic10
Diverticulum intestinal hemorrhagic10
Gastrointestinal hemorrhage11
Intra-abdominal hematoma10
Duodenal ulcer hemorrhage01
Hemorrhoidal hemorrhage01
Mouth hemorrhage01
SecondaryNumber of Participants With a Bleeding-related Adverse Event During the Treatment Period (Continued)

All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication.

Time frame:
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With a Bleeding-related Adverse Event During the Treatment Period (Continued)
ParticipantsApixiban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Hemorrhagic anemia2015
Ecchymosis59
Petechiae22
Hemorrhage subcutaneous10
Increased tendency to bruise05
Vaginal hemorrhage20
Menorrhagia10
Uterine hemorrhage01
Conjunctival hemorrhage10
Hematoma infection10
Spinal hematoma01
SecondaryNumber of Participants With Neurologic Adverse Events With Onset During the Treatment Period

Neurologic events were based on Medical Dictionary for Regulatory Activities search categories.For new or worsening events that were not related to the site of surgery, additional information was collected on a specific form. In addition, neurology consultation was to be obtained for these patients.

Time frame:
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Neurologic Adverse Events With Onset During the Treatment Period
ParticipantsApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Paraesthesia3219
Hypoaesthesia2935
Burning sensation75
Peroneal nerve palsy56
Hypotonia44
Dysarthria31
Paresis21
Cervicobrachial syndrome11
Coordination abnormal10
Hypertonia11
Neuropathy peripheral12
Peripheral nerve lesion11
Radiculitis10
Paralysis01
Muscular weakness711
Nerve injury21
Femoral nerve injury10
Sciatic nerve injury10
Peroneal nerve injury01
Diplopia10
Gait disturbance10
SecondaryNumber of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period

preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. MA criteria: Hemoglobin: \>2 g/dL decrease from preRx or value ≤ 8 g/dL; hematocrit (%): \<0.75\*preRx; platelet count (\*10\^9 cells/L): \<100,000/mm\^3; erythrocytes (\*10\^6 cells/μL): \<0.75\*preRx level; leukocytes (\*10\^3 cells/μL): \< 0.75\*LLN or \>1.25\*ULN, or if preRx LLN use \< 0.8\*preRx or \>ULN if preRx \>ULN use \>1.2\*preRx or \<LLN; basophils (\*10\^3 cells/μL): \>400/mm\^3; eosinophils (\*10\^3 cells/μL): \> 0.75\*10\^3 cells/μL; lymphocytes (\*10\^3 cells/μL): \>0.75\*10\^3 cells/μL; monocytes (\*10\^3 cells/μL): \>2000/mm\^3; neutrophils (\*10\^3 cells/μL): \<1.0;

Time frame:
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period
ParticipantsApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Hemoglobin, low (n=2605, 2587)21892218
Hematocrit, low (n=2554, 2536)12741350
Platelet count, low (n=2597, 2576)69
Erythrocytes, low (n=2558, 2540)13101377
Leukocytes, low (n=2632, 2617)5454
Leukocytes, high (n=2632, 2617)385360
Basophils (absolute), high (n=2629, 2613)13
Eosinophils (absolute), high (n=2629, 2613)7570
Lymphocytes (absolute), low (n=2629, 2613)383382
Lymphocytes (absolute), high (n=2629, 2613)33
Monocytes (absolute), high (n=2629, 2613)911
Neutrophils (absolute), low (n=2629, 2613)54
SecondaryNumber of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)

preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Alanine aminotransferase (ALT) (U/L): \>3 \*ULN: alkaline phosphatase (ALP) (U/L): \>2\* ULN; aspartate aminotransferase (ASP) (U/L): \>3 \*ULN; bilirubin, direct (mg/dL): \>2\*ULN; bilirubin, total (mg/dL): \>2\*ULN; BUN (mg/dL): \>2\*ULN; creatinine (mg/dL): \>1.5\*ULN; calcium (mg/dL): \< 0.8\*LLN or \>1.2 \*ULN, or if preRx \<LLN use \<0.75\* preRx or \>ULN if preRx \>ULN use \> 1.25\*preRx or \<LLN; chloride (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use \<0.9\*preRx or \>ULN if preRx \>ULN use \>1.1\* preRx or \<LLN; bicarbonate (mEq/L): \< 0.75\* LLN or \>1.25\*ULN, or if preRx \<LLN use \<0.75\*preRx or \>ULN if preRx \>ULN use \>1.25\*preRx or \<LLN; potassium (mEq/L): \< 0.9\*LLN or \>1.1\*ULN, or if preRx \<LLN use \<0.9\*preRx or \>ULN if preRx \>ULN use \>1.1\* preRx or \< LLN; sodium (mEq/L): \<0.95\* LLN or \>1.05×ULN, or if preRx \<LLN use \<0.95\* predose or \>ULN if preRx \>ULN use \>1.05 \*preRx or \< LLN.

Time frame:
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)
ParticipantsApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Alkaline phosphatase, high (n=2631, 2618)5557
Alanine aminotransferase, high (n=2629, 2616)5083
Aspartate aminotransferase, high (n=2629, 2616)7373
Bilirubin, direct, high (n=2622, 2604)145139
Bilirubin, total, high (n=2630, 2617)2412
Blood urea nitrogen (BUN), high (n=2618, 2598)1917
Creatinine, high (n=2618, 2598)2125
Calcium, total, low (n=2618, 2598)718
Calcium, total, high (n=2618, 2598)01
Chloride, serum, low (n=2615, 2594)66
Bicarbonate, low (n=2615, 2595)88
Potassium, serum, low (n=2614, 2594)7373
Potassium, serum, high (n=2614, 2594)6147
Sodium, serum, low (n=2615, 2594)2923
Sodium, serum, high (n=2615, 2594)54
SecondaryNumber of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)

preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Glucose, fasting (mg/dL): \<.8\*LLN or \>1.5\*ULN, or if preRx \<LLN use \<.8\*preRx or \>ULN if preRx \>ULN use \>2\*preRx or \<LLN; protein, total (g/L): If missing preRx use ≥2, or if value ≥4 or preRx =0 or .5 use ≥2, or if preRx=1 use ≥3, or if preRx =2 or 3 use ≥4; creatine kinase (U/L): \>5\*ULN; uric acid (mg/dL): \>.5\* ULN, or if preRx \>ULN use \>2\*preRx; blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx =2 or 3 use ≥4; glucose, urine : If missing preRx use ≥2, or if value ≥4, or if preRx=0 or .5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; RBC, urine (hpf): If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx dose= 1 use ≥3, or if preRx=2 or 3 use ≥4; WBC, urine (h): If missing preRx use ≥2, or if value ≥4, or if preRx =0 or .5 use ≥2, or if preRx =1 use ≥3, or if preRx=2 or 3 use ≥4.

Time frame:
First dose of study drug (presurgery) through 2 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued)
ParticipantsApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Glucose, fasting serum, high (n=14, 17)01
Protein, total, low (n=2618, 2596)747752
Protein, total, high (n=2618, 2596)31
Creatine kinase, high (n=2630, 2616)615642
Uric acid, high (n=2618, 2597)23
Blood, urine, high (n=2588, 2568)275234
Glucose, urine, high (n=2588, 2568)6876
Leukocyte esterase, urine, high (n=21, 41)04
Protein, urine (n=2588, 2568)169168
Red blood cells (RBC), urine, high (n=1310, 1230)216173
White blood cells (WBC),urine, high (n=1311, 1228)217229
SecondaryNumber of Participants With Adverse Events Related to Elevations in Liver Function Test Results With Onset During the Treatment Period

Treatment guidelines were provided for jaundice and elevated results of liver function tests.

Time frame:
First dose of study drug (presurgery) through 30 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Adverse Events Related to Elevations in Liver Function Test Results With Onset During the Treatment Period
ParticipantsApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
Aspartate aminotransferase increased4867
Alanine aminotransferase increased4061
Gamma-glutamyltransferase increased2754
Blood bilirubin increased177
Bilirubin conjugated increased1112
Hepatic enzyme increased916
Liver function test results abnormal49
Transaminases increased11
Cholelithiasis20
Hepatitis toxic20
Cholecystitis acute10
Cholestasis10
Hyperbilirubinemia10
Postcholecystectomy syndrome10
Cholecystitis01
Hepatic pain01
Hepatitis01
Hepatomegaly01
Jaundice cholestatic01
Hypoalbuminemia01
Hypoproteinemia01
Yellow skin01
SecondaryRates of Adjudicated Myocardial Infarction (MI)/Stroke, MI, Stroke, and Thrombocytopenia During the Intended Treatment Period

Event rate=Number of events divided by the number of patients evaluated. All suspected events were reported by investigator. Acute MI=the presence of a clinical situation (eg, abnormal history, physical examination, new electrocardiogram changes) suggestive of an MI and at least 1 of the following: elevated creatine kinase (CK)-MB or troponin T or troponin I ≥2\*upper limit of normal (ULN); if CK-MB or troponin values not available, total CK ≥2\*ULN; or new significant (≥0.04 sec) Q waves in ≥2 contiguous leads. Stroke=a new focal neurologic deficit of sudden onset lasting at least 24 hours that was not due to a readily identifiable nonvascular cause. Adjudication classified each reported stroke as primary hemorrhagic, nonhemorrhagic, infarction with hemorrhagic conversion, or unknown type. Thrombocytopenia=after 3 days as drop in platelet count to \<100,000/mm\^3 for patients with a baseline value \>150,000/mm\^3 or a \>50% decline, if the baseline value was ≤150,000/mm\^3.

Time frame:
Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
Reported as:
Number · Percent of events/patients evaluated
Rates of Adjudicated Myocardial Infarction (MI)/Stroke, MI, Stroke, and Thrombocytopenia During the Intended Treatment Period
Percent of events/patients evaluatedApixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus Placebo
MI/stroke0.22 (0.09 to 0.51)0.26 (0.12 to 0.56)
MI0.19 (0.07 to 0.46)0.11 (0.02 to 0.35)
Stroke0.04 (0.00 to 0.24)0.15 (0.05 to 0.41)
Thrombocytopenia0.07 (0.00 to 0.30)0.11 (0.02 to 0.35)
Statistical analysis
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Difference in event rates: -0.04 · 95% CI -0.34 to 0.26Apixaban-enoxaparin. MI/stroke
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Difference in event rates: 0.07 · 95% CI -0.17 to 0.34Apixaban-enoxaparin. MI
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Difference in event rates: -0.11 · 95% CI -0.35 to 0.07Apixaban-enoxaparin. Stroke
  • Apixaban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo · Difference in event rates: -0.04 · 95% CI -0.26 to 0.17Apixaban-enoxaparin. Thrombocytopenia

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixaban, 2.5 mg BID + Placebo—184/2,673 (6.9%)1,260/2,673 (47.1%)
Enoxaparin, 40 mg QD + Placebo—172/2,659 (6.5%)1,315/2,659 (49.5%)
Most frequent serious events
Showing 10 of 174
Most frequent serious events
EventApixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + Placebo
Deep vein thrombosisVascular disorders8/267318/2659
Dislocation of joint prosthesisInjury, poisoning and procedural complications5/267311/2659
Joint dislocationInjury, poisoning and procedural complications8/26737/2659
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/26737/2659
Device dislocationInjury, poisoning and procedural complications3/26737/2659
Wound infectionInfections and infestations7/26733/2659
Femur fractureInjury, poisoning and procedural complications6/26734/2659
Atrial fibrillationCardiac disorders6/26733/2659
HypotensionVascular disorders6/26734/2659
OverdoseInjury, poisoning and procedural complications5/26735/2659
Most frequent other events
Showing 10 of 12
Most frequent other events
EventApixaban, 2.5 mg BID + PlaceboEnoxaparin, 40 mg QD + Placebo
NauseaGastrointestinal disorders485/2673529/2659
Procedural painInjury, poisoning and procedural complications421/2673426/2659
ConstipationGastrointestinal disorders318/2673364/2659
HypotensionVascular disorders259/2673262/2659
VomitingGastrointestinal disorders211/2673262/2659
PyrexiaGeneral disorders236/2673242/2659
DizzinessNervous system disorders185/2673154/2659
Urinary retentionRenal and urinary disorders174/2673152/2659
Anaemia postoperativeInjury, poisoning and procedural complications163/2673156/2659
Oedema peripheralGeneral disorders156/2673141/2659

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Apixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus PlaceboTotal
Mean60.9 ± 11.7960.6 ± 11.8260.8 ± 11.81
Age, Customized
Age, Customized(Participants)Apixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus PlaceboTotal
Younger than 65 years160816053213
65 to younger than 75 years7707671537
75 years and older330327657
Sex: Female, Male
Sex: Female, Male(Participants)Apixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus PlaceboTotal
Female143014512881
Male127812482526
Region of Enrollment
Region of Enrollment(Participants)Apixaban, 2.5 mg BID Plus PlaceboEnoxaparin, 40 mg QD Plus PlaceboTotal
United States450441891
Spain322961
Ukraine217219436
Russian Federation274276550
Israel5756113
United Kingdom7778155
India5656112
France7574149
Hungary152150302
Mexico7374147
Canada359356715
Argentina5354107
Belgium5960119
Poland184185369
Romania242549
Australia10199200
Denmark9999198
Germany135134269
Norway474895
China121124245
Sweden6362125
08

Study locations

143 sites
  • Capstone Clinical Trials, Inc
    Birmingham, Alabama 35209, United States
  • West Alabama Research, Llc
    Birmingham, Alabama 35209, United States
  • Martin Bowen Hefley Orthopedics
    Little Rock, Arkansas 72205, United States
  • Orthoarkansas, P.A.
    Little Rock, Arkansas 72205, United States
  • Uc Davis Medical Center
    Sacramento, California 95817, United States
  • Colorado Orthopedic Consultants, Pc
    Aurora, Colorado 80012, United States
  • Advanced Orthopedic And Sports Medicine Specilists
    Denver, Colorado 80230, United States
  • Denver-Vail Orthopedics, P.C.
    Denver, Colorado 80230, United States
  • Pab Clinical Research
    Brandon, Florida 33511, United States
  • Research Alliance, Inc.
    Clearwater, Florida 33756, United States
  • Shrock Orthopedic Research
    Ft. Lauderdale, Florida 33316, United States
  • Phoenix Clinical Research, Llc
    Tamarac, Florida 33321, United States
  • Atlanta Knee And Sports Medicine
    Decatur, Georgia 30033, United States
  • Americana Orthopedics
    Boise, Idaho 83702, United States
  • Bosie Orthopedic Clinic
    Meridian, Idaho 83642, United States
  • University Orthopedic Center
    Altoona, Pennsylvania 16602, United States
  • Gill Orthopedic Center
    Lubbock, Texas 79410, United States
  • Robert R. King, Md
    Lubbock, Texas 79410, United States
  • Unlimited Research
    San Antonio, Texas 78217, United States
  • Local Institution
    Capital Federal, Buenos Aires C1199ACK, Argentina
  • Local Institution
    Capital Federal, Buenos Aires C1280AEB, Argentina
  • Local Institution
    Capital Federal, Buenos Aires C1425AGP, Argentina
  • Local Institution
    Ciudad De Buenos Aires, Buenos Aires C1426BOS, Argentina
  • Local Institution
    Coronel Suarez, Buenos Aires B7540GHD, Argentina
  • Local Institution
    Monte Grande, Buenos Aires B1842DID, Argentina
  • Local Institution
    Camperdown, New South Wales 2050, Australia
  • Local Institution
    Kogarah, New South Wales 2217, Australia
  • Local Institution
    Lismore, New South Wales 2480, Australia
  • Local Institution
    Southport, Queensland 4215, Australia
  • Local Institution
    Bedford Park, South Australia 5042, Australia
  • Local Institution
    Box Hill, Victoria 3128, Australia
  • Local Institution
    Malvern, Victoria 3144, Australia
  • Local Institution
    Windsor, Victoria 3181, Australia
  • Local Institution
    Perth, Western Australia 6000, Australia
  • Local Institution
    Antwerp, 2020, Belgium
  • Local Institution
    Brasschaat, 2930, Belgium
  • Local Institution
    Genk, 3600, Belgium
  • Local Institution
    Hasselt, 3500, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Edmonton, Alberta T6G 2B7, Canada
  • Local Institution
    Ajax, Ontario L1S 2J5, Canada
  • Local Institution
    Cambridge, Ontario N1R 7L7, Canada
  • Local Institution
    Chatham, Ontario N7L 4T1, Canada
  • Local Institution
    Guelph, Ontario N1E 6L9, Canada
  • Local Institution
    Newmarket, Ontario L3Y 5G8, Canada
  • Local Institution
    Oshawa, Ontario L1J 2J2, Canada
  • Local Institution
    Sarnia, Ontario N7T 6H3, Canada
  • Local Institution
    Scarborough, Ontario M1S 4T7, Canada
  • Local Institution
    St. Catharines, Ontario L2R 7P3, Canada
  • Local Institution
    Stratford, Ontario N5A 2N4, Canada
  • Local Institution
    Waterloo, Ontario N2J 1C4, Canada
  • Local Institution
    Windsor, Ontario N8W 1E6, Canada
  • Local Institution
    Montreal, Quebec H3G 1A4, Canada
  • Local Institution
    Quebec, G1L 3L5, Canada
  • Local Institution
    Beijing, Beijing 100035, China
  • Local Institution
    Beijing, Beijing 100853, China
  • Local Institution
    Guangzhou, Guangdong 510405, China
  • Local Institution
    Qingdao, Shandong 266003, China
  • Local Institution
    Shanghai, Shanghai 200011, China
  • Local Institution
    Shanghai, Shanghai 200025, China
  • Local Institution
    Shanghai, Shanghai 200233, China
  • Local Institution
    Amager, 2300, Denmark
  • Local Institution
    Frederiksberg, 2000, Denmark
  • Local Institution
    Herlev, 2730, Denmark
  • Local Institution
    Horsholm, 2970, Denmark
  • Local Institution
    Hvidovre, 2650, Denmark
  • Local Institution
    Kobenhavn Nv, 2400, Denmark
  • Local Institution
    Silkeborg, 8600, Denmark
  • Local Institution
    Nice, 06200, France
  • Local Institution
    Paris, 75014, France
  • Local Institution
    Paris, 75019, France
  • Local Institution
    Paris, 75679, France
  • Local Institution
    Saint Etienne, 42100, France
  • Local Institution
    Saint-Saulve, 59880, France
  • Local Institution
    Frankfurt / Main, 65929, Germany
  • Local Institution
    Frankfurt, 60528, Germany
  • Local Institution
    Rheinfelden, 79618, Germany
  • Local Institution
    Budapest, 1081, Hungary
  • Local Institution
    Kecskemet, 6000, Hungary
  • Local Institution
    Szeged, 6720, Hungary
  • Local Institution
    Szolnok, 5000, Hungary
  • Local Institution
    Ahmedabad, Gujarat 380015, India
  • Local Institution
    Ludhiana, Punjab 141001, India
  • Local Institution
    Lucknow, Uttar Prsdesh 226003, India
  • Local Institution
    Bangalore, 560034, India
  • Local Institution
    Mangalore, 575001, India
  • Local Institution
    Beer Sheva, 84101, Israel
  • Local Institution
    Haifa, 31096, Israel
  • Local Institution
    Holon, 58100, Israel
  • Local Institution
    Kfar-Saba, 44281, Israel
  • Local Institution
    Zerifin, 70300, Israel
  • Local Institution
    Tijuana, Baja California 22010, Mexico
  • Local Institution
    Mexico City, Distrito Federal 06726, Mexico
  • Local Institution
    Mexico City, Distrito Federal 07760, Mexico
  • Local Institution
    Guadalajara, Jalisco 45235, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64460, Mexico
  • Local Institution
    Cd. Madero, Tamaulipas 89240, Mexico
  • Local Institution
    Aguascalientes, 20010, Mexico
  • Local Institution
    Chihuahua, 31020, Mexico
  • Local Institution
    Gjettum, 1346, Norway

Showing the first 100 of 143 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16. PubMed 35570249 ↗
  • Pineo GF, Gallus AS, Raskob GE, Chen D, Ramirez LM, Ramacciotti E, Lassen MR, Wang L. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar;11(3):444-51. doi: 10.1111/jth.12109. PubMed 23279103 ↗
  • Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23;363(26):2487-98. doi: 10.1056/NEJMoa1006885. PubMed 21175312 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 4 years 8 months after primary completion. A results delay was requested in Jun 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2007
First posted
Jan 18, 2007
Start
Mar 2007
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results delay requested
Jun 21, 2011
Results first posted
May 14, 2014
Last update
May 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00423319
Responsible party
Sponsor
First posted
Jan 18, 2007
Start date
Mar 2007
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
May 14, 2014
Last update
May 14, 2014

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin

Start the discussion